Form 8-K - Current report:
SEC Accession No. 0001104659-23-000616
Filing Date
2023-01-04
Accepted
2023-01-04 07:00:36
Documents
12
Period of Report
2022-12-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm231546d1_8k.htm   iXBRL 8-K 25510
  Complete submission text file 0001104659-23-000616.txt   197475

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA clrb-20221230.xsd EX-101.SCH 3036
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE clrb-20221230_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clrb-20221230_pre.xml EX-101.PRE 22597
6 EXTRACTED XBRL INSTANCE DOCUMENT tm231546d1_8k_htm.xml XML 3494
Mailing Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932 (608) 441-8120
Cellectar Biosciences, Inc. (Filer) CIK: 0001279704 (see all company filings)

IRS No.: 043321804 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36598 | Film No.: 23504329
SIC: 2834 Pharmaceutical Preparations